JP2009502780A5 - - Google Patents

Download PDF

Info

Publication number
JP2009502780A5
JP2009502780A5 JP2008522796A JP2008522796A JP2009502780A5 JP 2009502780 A5 JP2009502780 A5 JP 2009502780A5 JP 2008522796 A JP2008522796 A JP 2008522796A JP 2008522796 A JP2008522796 A JP 2008522796A JP 2009502780 A5 JP2009502780 A5 JP 2009502780A5
Authority
JP
Japan
Prior art keywords
quinolin
pyrrolo
amido
pyridin
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008522796A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009502780A (ja
JP5242391B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/025377 external-priority patent/WO2007018818A1/en
Publication of JP2009502780A publication Critical patent/JP2009502780A/ja
Publication of JP2009502780A5 publication Critical patent/JP2009502780A5/ja
Application granted granted Critical
Publication of JP5242391B2 publication Critical patent/JP5242391B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008522796A 2005-07-22 2006-06-29 Tgf−ベータ阻害剤としてのピリジンキノリン置換ピロロ[1,2−b]ピラゾール一水和物 Expired - Fee Related JP5242391B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70164105P 2005-07-22 2005-07-22
US60/701,641 2005-07-22
PCT/US2006/025377 WO2007018818A1 (en) 2005-07-22 2006-06-29 A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor

Publications (3)

Publication Number Publication Date
JP2009502780A JP2009502780A (ja) 2009-01-29
JP2009502780A5 true JP2009502780A5 (cg-RX-API-DMAC7.html) 2009-08-20
JP5242391B2 JP5242391B2 (ja) 2013-07-24

Family

ID=37450942

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008522796A Expired - Fee Related JP5242391B2 (ja) 2005-07-22 2006-06-29 Tgf−ベータ阻害剤としてのピリジンキノリン置換ピロロ[1,2−b]ピラゾール一水和物

Country Status (16)

Country Link
US (1) US7872020B2 (cg-RX-API-DMAC7.html)
EP (1) EP1910370B1 (cg-RX-API-DMAC7.html)
JP (1) JP5242391B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0613639A2 (cg-RX-API-DMAC7.html)
CA (1) CA2616196C (cg-RX-API-DMAC7.html)
DK (1) DK1910370T3 (cg-RX-API-DMAC7.html)
ES (1) ES2542425T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20150474T1 (cg-RX-API-DMAC7.html)
HU (1) HUE025209T2 (cg-RX-API-DMAC7.html)
IL (1) IL188181A (cg-RX-API-DMAC7.html)
MX (1) MX2008001020A (cg-RX-API-DMAC7.html)
PL (1) PL1910370T3 (cg-RX-API-DMAC7.html)
PT (1) PT1910370E (cg-RX-API-DMAC7.html)
RS (1) RS53999B1 (cg-RX-API-DMAC7.html)
SI (1) SI1910370T1 (cg-RX-API-DMAC7.html)
WO (1) WO2007018818A1 (cg-RX-API-DMAC7.html)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
RU2612958C2 (ru) 2011-07-13 2017-03-14 Ск Кемикалз Ко., Лтд. 2-пиридилзамещенные имидазолы в качестве ингибиторов alk5 и/или alk4
EP2917365B1 (en) 2012-11-12 2020-03-11 Institució Catalana de Recerca i Estudis Avançats Methods and kits for the prognosis of colorectal cancer
BR112015023261A2 (pt) 2013-03-14 2017-07-18 Massachusetts Inst Technology composições e métodos para expansão e cultura de células-tronco epiteliais
CN107073042A (zh) 2014-09-03 2017-08-18 布里格海姆妇女医院公司 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
EP3277673B1 (en) 2015-04-01 2022-05-04 Rigel Pharmaceuticals, Inc. Tgf-beta inhibitors
JP6980534B2 (ja) 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大、富化、および維持に関する方法および組成物
US10450318B2 (en) 2015-12-15 2019-10-22 Bristol-Myers Squibb Company CXCR4 receptor antagonists
CA3010610A1 (en) 2016-01-08 2017-07-13 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
US10604528B2 (en) 2016-07-07 2020-03-31 Crystal Pharmaceutical (Suzhou) Co., Ltd. Galunisertib crystalline form, preparation method thereof and use thereof
WO2018068759A1 (zh) 2016-10-14 2018-04-19 江苏恒瑞医药股份有限公司 五元杂芳环并桥环类衍生物、其制备方法及其在医药上的应用
AU2017386417B2 (en) 2016-12-30 2022-07-14 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
WO2018165979A1 (zh) * 2017-03-17 2018-09-20 杭州领业医药科技有限公司 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的晶型及其制备方法和药物组合物
WO2018170724A1 (zh) 2017-03-21 2018-09-27 杭州领业医药科技有限公司 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶,其制备方法和药物组合物
WO2019042383A1 (zh) * 2017-08-31 2019-03-07 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
WO2019105082A1 (zh) * 2017-11-30 2019-06-06 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
WO2019137027A1 (zh) * 2018-01-12 2019-07-18 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
ES3038913T3 (en) 2018-03-20 2025-10-15 Icahn School Med Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
US20210254006A1 (en) 2018-06-06 2021-08-19 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
WO2020037323A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
CA3124700A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CN115282280A (zh) * 2022-08-12 2022-11-04 中国科学技术大学 TGF-β1信号抑制剂的新用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
GB202309553D0 (en) 2023-06-24 2023-08-09 Ucl Business Ltd Compostions and uses thereof
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1397364T1 (sl) * 2001-05-24 2007-12-31 Lilly Co Eli Novi pirolni derivati kot farmacevtske uäśinkovine
EP1567528A1 (en) * 2002-11-21 2005-08-31 Eli Lilly And Company Mixed lineage kinase modulators
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles

Similar Documents

Publication Publication Date Title
HRP20151299T1 (hr) Kristalni (r)-(e)-2-(4-(2-(5-(1-(3,5-diklorpiridin-4-il)etoksi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol i njegova upotreba kao inhibitora fgfr
JP2011168587A5 (cg-RX-API-DMAC7.html)
FI2134702T4 (fi) 6-[2-(metyylikarbamoyyli)fenyylisulfanyyli]-3-E-[2-(pyridiini-2-yyli)etenyyli]indatsolin kidemuotoja jotka soveltuvat nisäkkäiden poikkeavan solukasvun hoitamiseen
WO2005046589A3 (en) Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
WO2009066326A3 (en) Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts
WO2010026436A3 (en) 1,3, 4, 6, 7, 11b-hexahydro-benzo[alpha]quinolizines for the treatment of hyperkinetic movement and related disorders
RU2007110026A (ru) ПОЛИМОРФНЫЕ И АМОРФНАЯ ФОРМЫ ФОСФАТНОЙ СОЛИ 8-ФТОР-2-{4-[(МЕТИЛАМИНО)МЕТИЛ]ФЕНИЛ}-1,3,4,5-ТЕТРАГИДРО-6Н-АЗЕПИНО[5.4.3-cd]ИНДОЛ-6-ОНА
WO2007076348A3 (en) Azaindole inhibitors of aurora kinases
WO2009080227A3 (en) Pyrazole-carboxamide derivatives as p2y12 antagonists
JP2017519027A5 (cg-RX-API-DMAC7.html)
WO2008044243A3 (en) Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
WO2007048066A3 (en) Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators
WO2009080226A3 (en) Heterocyclic pyrazole-carboxamides as p2y12 antagonists
JP2012512158A5 (cg-RX-API-DMAC7.html)
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2008048867A3 (en) Bicyclic heteroaromatic compounds
CA2616196A1 (en) A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor
WO2010089510A3 (fr) Dérivés d'azaspiranyl-alkylcarbamates d'hétérocycles à 5 chaînons, leur préparation et leur application en thérapeutique
JP2005517696A5 (cg-RX-API-DMAC7.html)
WO2009149139A8 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2009013348A3 (en) Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
WO2007081597A3 (en) Peri condensed tricyclic compounds useful as antibacterial agents
JP2020502224A5 (cg-RX-API-DMAC7.html)
JP2013514974A5 (cg-RX-API-DMAC7.html)
WO2009047499A3 (en) Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processes